Institutional Fund
Prosight Management, LP
Dallas, TXCIK 16172015 filings on record
Portfolio Value
$609.82M
Q1 2026
Holdings
46
Reported positions
New Buys
16
Opened this quarter
QoQ Change
+26.0%
from $483.93M
Portfolio Value Trend
Reported 13F value by quarter
Portfolio value trend — upgrade to see history
UpgradeTop Allocations
Largest positions by weight
- Nektar Therapeutics8.7%
- Boston Scientific Corp8.2%
- Janux Therapeutics Inc8.1%
- Procept Biorobotics Corp8.0%
- Galapagos NV7.6%
- Genedx Holdings Corp5.5%
- Other53.9%
Portfolio Holdings
46 positions · Q1 2026
| # | Security | Shares | Value | % Port. | Δ Shares | Activity |
|---|---|---|---|---|---|---|
| 1 | Nektar Therapeutics | 735.0K | $52.88M | 8.7% | +180.4K | Added |
| 2 | Boston Scientific Corp | 795.5K | $49.92M | 8.2% | +585.5K | Added |
| 3 | Janux Therapeutics Inc | 3.55M | $49.34M | 8.1% | +1.16M | Added |
| 4 | Procept Biorobotics Corp | 1.95M | $48.64M | 8.0% | +565.0K | Added |
| 5 | Galapagos NV | 1.55M | $46.50M | 7.6% | +475.9K | Added |
| 6 | Genedx Holdings Corp | 523.5K | $33.62M | 5.5% | +468.5K | Added |
| 7 | Shattuck Labs Inc | 5.00M | $32.18M | 5.3% | +2.62M | Added |
| 8 | Adc Therapeutics SA | 8.30M | $31.13M | 5.1% | −177.3K | Reduced |
| 9 | Kura Oncology Inc | 3.36M | $27.29M | 4.5% | +827.1K | Added |
| 10 | Alnylam Pharmaceuticals Inc | 76.0K | $25.15M | 4.1% | +58.9K | Added |
36 more holdings on Premium
See this fund's complete portfolio, full position changes, and activity history.
Unlock full portfolio